Literature DB >> 19211405

High-dose insulin therapy: is it time for U-500 insulin?

Wendy S Lane1, Elaine K Cochran, Jeffrey A Jackson, Jamie L Scism-Bacon, Ilene B Corey, Irl B Hirsch, Jay S Skyler.   

Abstract

OBJECTIVE: To provide an overview of U-500 regular insulin action, review published clinical studies with U-500 regular insulin, and offer guidance to practicing endocrinologists for identifying patients for whom U-500 regular insulin may be appropriate.
METHODS: This review has been produced through a synthesis of relevant published literature compiled via a literature search (MEDLINE search of the English-language literature published between January 1969, and July 2008, related to U-500, insulin resistance, concentrated insulin, high-dose insulin, insulin pharmacokinetics, and diabetes management) and the authors' collective clinical experience.
RESULTS: The obesity epidemic is contributing to an increase in the prevalence of type 2 diabetes, as well as to increasing insulin requirements in insulin-treated patients. Many of these patients exhibit severe insulin resistance, manifested by daily insulin requirements of 200 units or greater or more than 2 units/kg. Delivering an appropriate insulin volume to these patients can be difficult and inconvenient and may be best accomplished with U-500 regular insulin by multiple daily injections or with continuous subcutaneous insulin infusion, rather than with standard U-100 insulin. Implementation of U-500 regular insulin in patients previously on other insulin formulations is described with a treatment algorithm covering dosage requirements ranging from 150 to more than 600 units per day on the basis of the authors' experience.
CONCLUSIONS: Regimen conversion of appropriately selected patients from high-dose, U-100 insulin to U-500 regular insulin therapy on the basis of the recommendations presented in this article may potentially result in improved glycemic control and lower cost.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211405     DOI: 10.4158/EP.15.1.71

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  31 in total

1.  U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes.

Authors:  Jolene Brown Lowery; Amy C Donihi; Mary T Korytkowski
Journal:  Diabetes Technol Ther       Date:  2012-02-24       Impact factor: 6.118

Review 2.  Clinical use of U-500 regular insulin: review and meta-analysis.

Authors:  Sirimon Reutrakul; Kristen Wroblewski; Rebecca L Brown
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

3.  A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections.

Authors:  Juan P Frias; Bruce W Bode; Timothy S Bailey; Mark S Kipnes; Rocco Brunelle; Steven V Edelman
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

4.  Use of U-500 regular insulin via continuous subcutaneous insulin infusion: clinical practice experience.

Authors:  Sirimon Reutrakul; Rebecca L Brown; Chung-Kay Koh; Tiffany K Hor; David Baldwin
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

5.  Paradigm shift in the management of type B insulin resistance.

Authors:  Jun Hwa Hong; Hyun Jin Kim; Kang Seo Park; Bon Jeong Ku
Journal:  Ann Transl Med       Date:  2018-12

Review 6.  Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.

Authors:  Rebecca Schechter; Sirimon Reutrakul
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

Review 7.  Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions.

Authors:  Jeremy L Johnson; Jessica M Downes; Cassandra K Obi; Nana B Asante
Journal:  J Diabetes Sci Technol       Date:  2016-11-28

Review 8.  Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus.

Authors:  Alexandria M Dailey; Lisa R Tannock
Journal:  Curr Diab Rep       Date:  2011-04       Impact factor: 4.810

9.  Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin.

Authors:  Amparo de la Peña; Xiaosu Ma; Shobha Reddy; Fernando Ovalle; Richard M Bergenstal; Jeffrey A Jackson
Journal:  J Diabetes Sci Technol       Date:  2014-05-12

10.  U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients.

Authors:  Mayer B Davidson; Maria D Navar; Diana Echeverry; Petra Duran
Journal:  Diabetes Care       Date:  2009-11-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.